Aims: Monoclonal antibodies against tumor-related molecules are therapeutic agents for cancers. Promising results support the use of monoclonal antibodies in several cancers such as lung and breast cancer. However, using monoclonal antibodies as therapeutic agents to treat hepatocellular carcinoma (HCC), a major type of liver cancer, is still at the beginning. We have previously generated a monoclonal antibody against cadherin-17 (CDH17), named Lic5. This antibody has proven anti-tumor and cisplatin-sensitizing effect in HCC using a subcutaneous tumor xenograft mouse model. Chan et al.; JALSI, 4(3): 1-10, 2016; Article no.JALSI.22188 2 Study Design and Methodology: To further consolidate our previous finding, we tested the effect of Lic5 alone or in combination with cisplatin or epirubicin on tumor growth inhibition and animal survival using a more advanced orthotopic tumor xenograft model. Results: Single Lic5, cisplatin and epirubicin treatment inhibited growth of cultured HCC cells using cell proliferation assay, while more significant reductions were observed when cisplatin or epirubicin was used together with Lic5. Similar trends of growth inhibition were observed when the same experimental grouping was applied to treat orthotopic tumor-bearing nude mice. Treatment of Lic5 enhanced survivals of orthotopic tumor-bearing nude mice when compared to the control group. Among all experimental groups, combined Lic5 and epirubicin group yielded the best survival. For next phase antibody humanization, we also identified the complementarity determining regions (CDRs) on variable regions on the light and heavy chain of Lic5. Conclusion: Together, we have validated the preclinical use of Lic5 in an orthotopic HCC xenograft model. Our successful identification of CDRs constitutes the first step in synthesizing humanized Lic5.
INTRODUCTION
Global incidence of liver cancer ranks top among various gastrointestinal cancers. More than half a million new cases appear each year, concordant with an approximately equal number of deaths annually. Hepatocellular carcinoma (HCC) is a major type of liver cancer, contributing up to more than 80% of total cases. Resectable patients can be treated by frontline tumor resection, while such curative treatment does not benefit advanced stage patients presented with multi-nodal or even metastatic tumors. Unlike a number of solid tumors that can be treated quite effectively using chemotherapeutic drugs, HCC is rather resistant to traditional chemotherapeutics including cisplatin and epirubicin. Although molecular targeting drug Sorafenib, a multikinase inhibitor, is clinically approved for treating unresectable, advanced stage patients, its drug efficacy is modest. To improve this clinical situation and to offer new treatment options for patients not amendable for current therapies, it is our longstanding efforts to research for HCCrelated molecules for therapeutic targeting.
Cadherin-17 (CDH17) is an oncofetal molecule first identified by our group to be overexpressed in more than half of the HCC cases [1] . Later studies further demonstrated the clinical correlation of CDH17 overexpression with advanced HCC condition such as tumor invasion and late stage tumor [2, 3] . We deciphered its tumorigenic mechanism by showing its intersection with a frequently deregulated Wnt/β-catenin pathway in HCC that leads to the formation of a novel CDH17/β-catenin axis. Activation of this axis stimulates the expression of several tumorigenic molecules including cell cycle regulator cyclin D1 [3, 4] . Besides, we also unraveled its tumorigenic effects in cultured HCC cells and their derived tumor xenografts in nude mice using a series of functional assays and animal models. These prior studies have put forth the concept of targeting CDH17 for therapy. Exogenous suppression of CDH17 using RNA interference or our in-house generated monoclonal antibody against CDH17 (Lic5) significantly reduced growth of subcutaneous HCC tumors [3, 5] . Enhanced suppression on growth of subcutaneous tumors was observed when we combined the use of Lic5 with a conventional chemotherapeutic cisplatin [5] . Our prior results have undoubtedly described the tumor-suppressing effect of Lic5 and its cisplatinsensitizing effect.
Along this research line, this study performed indepth analyses on the tumor-suppressing and chemosensitizing effects of Lic5 on a more clinically relevant orthotopic HCC xenograft model. In addition, we also exploited the complementarity determining regions (CDRs) on the variable regions of heavy chain and light chain of Lic5, for which this information is essential for reducing the immunogenicity of mouse antibody through antibody humanization before clinical application. In all, this study consolidates the preclinical usefulness of Lic5 on HCC by a more advanced animal model. The derived CDR information can lay as a foundation for next phase production of humanized Lic5 for clinical use.
MATERIALS AND METHODS

Human HCC Cell Lines
Human HCC cell lines MHCC97-L (97L) and PLC/PRF/5 (PLC) were used as before [6, 7] . 
Production and Characterization of
Lic5, an in-house Monoclonal Antibody against CDH17
An in-house hybridoma cell line secreting Lic5 was generated as described [5] . Hybridoma cells were maintained in DMEM supplemented with 10% FBS and 100 units/ml penicillin and streptomycin. To collect Lic5, hybridoma cells were cultured in serum-free hybridoma-SFM (Life Technologies) for 6 days. Cultured supernatant was collected and purified using Protein G column (Life Technologies). Concentration of the purified Lic5 was estimated using RC DC Protein Assay (Bio-Rad, Hercules, CA, USA). Purity of Lic5 was assessed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) under reducing condition, followed by Coomassie Blue staining. Immunoreactivity and specificity of Lic5 was confirmed by western blot using 97L cell lysate and by immunohistochemistry using paraffin-embedded human HCC tissue. The use of clinical specimen for research was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB). The procedures for SDS-PAGE, Coomassie Blue staining and western blot were routinely performed [8] [9] [10] , while the method for immunohistochemistry was described below.
In vitro Cell Proliferation Assay
Pre-determined number of 97L and PLC cells was seeded onto 96-well culture plates for 1 day before treatment with Lic5 and/or chemotherapeutic drugs, cisplatin (Pharmachemie BV, Netherlands) and epirubicin (Pfizer, New York, NY, USA). Cells were subjected to the following treatments for 2 days:
(1) 150 µg/ml Lic5; (2) 0.156 µg/ml and 0.625 µg/ml cisplatin for 97L and PLC cells, respectively; (3) 0.04 µg/ml and 0.01 µg/ml epirubicin for 97L and PLC cells, respectively; (4) combined treatment of Lic5 and cisplatin; (5) combined treatment of Lic5 and epirubicin; (6) 150 µg/ml mouse IgG (Sigma-Aldrich, St Louis, MO, USA) as a control for Lic5. After treatment, proliferation of treated cells was measured using Cell Proliferation Kit I (Roche, Indianapolis, IN, USA) and as described [10] . In brief, MTT reagent was incubated with the treated cells for 4 hours. Colorimetric signals were then measured after addition of 10% SDS. Independent cell proliferation MTT assays were performed at least twice for result confirmation.
Orthotopic Tumor Xenograft Model
Male nude mice were obtained from Laboratory Animal Unit of The University of Hong Kong, Hong Kong. Animals were housed in individually ventilated cages under a 12-hour light/12-hour dark cycle and with free access to autoclaved water and chow. Animal experiments performed in this study were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) of our institute. To allow in vivo viewing of the growing orthotopic liver tumors, previously established luciferase-labelled 97L cell line was used [11] . 5 x 10 6 luciferaselabelled 97L cells were injected subcutaneously into nude mice to allow the growth of the subcutaneous tumors. These subcutaneous tumors were harvested when their sizes reached 200-300 mm 3 and used as tumor seeds to establish orthotopic liver tumors in a separate group of nude mice following the standard procedure [11] . Five days after orthotopic tumor implantation, mice received different treatments as following via intraperitoneal administration 3 times/week for 3 weeks (10-11 mice in each group): (1) 6 mg/kg Lic5; (2) 1 mg/kg cisplatin; (3) 1 mg/kg epirubicin; (4) combined treatment of Lic5 and cisplatin; (5) combined treatment of Lic5 and epirubicin; (6) 6 mg/kg mouse IgG as Lic5 control. Every week after treatment, orthotopic tumor growth and metastasis were monitored by live imaging in an IVIS 100 In Vivo Imaging System (Perkin Elmer, Waltham, MA, USA) after intraperitoneal injection of 150 mg/kg potassium luciferin (Gold Biotechnology, St Louis, MO, USA). For each measurement, a net photon count was obtained for each tumor. At the end of the experiment, orthotopic tumors were collected and subjected for formalin fixation and paraffin embedding.
Animal Survival Study
Orthotopic liver tumors were established as above using 97L cells. Orthotopic tumor-bearing mice received the following treatments intraperitoneally 3 times/week for 3 weeks (11-15 mice in each group): (1) 8 mg/kg Lic5; (2) 1 mg/kg cisplatin; (3) 1 mg/kg epirubicin; (4) combined treatment of Lic5 and cisplatin; (5) combined treatment of Lic5 and epirubicin; (6) 8 mg/kg mouse IgG as Lic5 control. Animal survival was continuously monitored till 6 weeks after treatment.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded orthotopic tumor xenografts and human HCC specimen as described [10, 12] .
In brief, 6 µm sections were prepared for deparaffinization and rehydration. After antigen retrieval and hydrogen peroxide treatment, sections were blocked with 3% bovine serum albumin before staining with mouse monoclonal antibody against β-catenin (1:200; BD Biosciences, San Jose, CA, USA) and Lic5
(0.0625 µg/ml) overnight at 4°C. Signals were detected using EnVision+ System-HRP Labelled Polymer Anti-mouse (Dako, Carpinteria, CA, USA) and visualized using Liquid DAB+ Substrate Chromogen System (Dako). Counterstaining was performed using hematoxylin. Images were captured using DXM1200F digital camera (Nikon, Melville, NY, USA).
Cloning of Variable Regions of Lic5
Total RNA was extracted from Lic5-secreting hybridoma cells using TRIzol reagent (Life Technologies) and converted to cDNA using SuperScript III First-Strand Synthesis System (Life Technologies). Variable region cDNA fragments from heavy chain and light chain of Lic5 were amplified using Ig-Primer Set (Novagen, Germany) and Platinum Taq DNA Polymerase High Fidelity (Life Technologies). Variable region of light chain was amplified by the 5' variable region primer (5'-ATGGAGACAGACACACTCCTGCTAT-3') and 3' primer on the constant region, while variable region of heavy chain was obtained by the 5' variable region primer (5'-ATGAACTTYGGGYTSAGMTTGRTTT-3', in which Y=C/T, S=C/G, M=A/C, and R=A/G) and 3' primer on the constant region. PCR products after resolving on a 1.5% agarose gel were purified and sequenced (BGI, Hong Kong).
Identification of CDR of Lic5
The nucleotide sequences of variable region of heavy chain and light chain of Lic5 were used to derive the amino acid sequences, which were then numbered according to Kabat numbering scheme. CDR was identified according to Kabat definition (www.bioinf.org.uk).
Statistical Analyses
Statistical analyses were performed using SPSS version 19 (SPSS Inc., Chicago, IL, USA). Data presented in bar chart are expressed as mean ± SD/SEM. Student's t-test was used to calculate the significance of difference between treatment groups and control group in both cell proliferation MTT assay and animal tumor xenograft experiments.
Kaplan-Meier method was employed for survival analyses, while the differences in survival were calculated using logrank test. A p-value of less than 0.05 was considered statistically significant.
RESULTS
Establishment of a Pipeline for Purifying Large Quantity of Lic5 from Hybridoma Cell Culture Supernatant
To obtain Lic5 with high purity and quantity for in vitro and in vivo experiments, we cultured Lic5-secreting hybridoma cells in serum-free medium. Our established pipeline for purifying Lic5 achieved a good antibody purity and yield. Coomassie Blue staining result revealed two prominent bands of about 55 and 27 kDa corresponding to the heavy and light chain of antibody on Day 6 culture supernatant, while these bands were not observed on Day 1 culture supernatant. With the presence of detectable level of antibody, culture supernatant collected on Day 6 was subjected to Protein G affinity chromatography for antibody purification. Successful binding of antibody onto the Protein G column was confirmed when we failed to detect the presence of antibody in the flowthrough after loading Day 6 culture supernatant onto the column. Antibody elution performed on different fractions (eluent E1 to E4) revealed the second and third elution fraction contained most abundant antibody. The two stained bands corresponding to the heavy and light chain of the antibody are the predominant bands detected on the protein gel, implicating our antibody purity with more than 90% (Fig. 1A) . Using our antibody purification pipeline, we managed to collect a favorable antibody amount of 23.88±6.96 mg Lic5 from each liter of culture supernatant collected on Day 6. The purified Lic5 demonstrated high immunoreactivity against CDH17. A single band of about 120 kDa corresponding to the apparent molecular weight of CDH17 was detected in CDH17-expressing 97L cells when we used Lic5 as a primary antibody for western blot (Fig. 1B) . When Lic5 was used for immunohistochemistry to detect CDH17 in human HCC tissue, discrete stains appeared at the cell membrane and cytoplasm (Fig. 1C) . The immunohistochemical stains generated by using Lic5 in this study was similar to the previous report with the use of a commercial antibody against CDH17 for immunohistochemistry [1].
Survival Benefit of Lic5
Our previous report has demonstrated the chemosensitizing effect of Lic5 towards a commonly used chemotherapeutic drug cisplatin in a subcutaneous tumor xenograft model [5] . To consolidate our earlier finding, we examined the chemosensitizing effect of Lic5 towards another chemotherapeutic drug epirubicin, which is also commonly used in HCC. Besides, we performed the drug testing with or without Lic5 in a more clinically relevant orthotopic tumor xenograft model.
Before treating orthotopic tumor-bearing mice with the purified Lic5, we first examined the antitumor effect of Lic5 alone or combined with cisplatin or epirubicin in cultured HCC cell lines in vitro using cell proliferation MTT assay (Fig. 2A) . When we performed cell proliferation assay on cultured 97L cells, treatment with cisplatin and epirubicin for 2 days resulted in 31.6% and 21.9% growth inhibition, respectively. Combination with Lic5 further enhanced the growth inhibition effect by 1.74-fold for cisplatin and 1.98-fold for epirubicin, which led to a growth inhibition of 55.1% and 43.3%, respectively ( Fig. 2A, left panel) . Similar growth inhibition was observed in cultured PLC cells, in which treatment with cisplatin resulted in 37.6% growth inhibition and combined treatment with Lic5 further increased the growth inhibition by 1.73-fold (65.2%). Unlike the significant growth inhibition of epirubicin on cultured 97L cells, this drug only inhibited growth of cultured PLC cells by 8.1%. Likewise, its combination with Lic5 enhanced the growth inhibition by 4.62-fold and led to a significant inhibition of 37.4% (Fig. 2,  right panel) . [1] (Fig. 2B) . At the end of the experiment, we collected the orthotopic tumors for analyzing the expression and localization of β-catenin, which is known as a downstream molecule of CDH17 and is a key member of the Wnt signaling pathway. Both combined treatment of Lic5 with cisplatin or epirubicin reduced the overall expression and cytoplasmic localization of β-catenin when compared to single treatment of chemotherapeutic drugs (Supplementary Fig. 1 ). Such immunohistochemical results further strengthen the tumor-suppressing effect mediated by Lic5 via its action on altering the expression and localization of β-catenin.
Fig. 1. Purification of Lic5 and its characterization
Lic5 was purified using Protein G affinity chromatography from culture supernatant of Lic5-secreting hybridoma cell line. (A) As shown on the Coomassie Blue-stained gel, culture supernatant (culture S/N) from Day 6 (D6) contained higher antibody amount than Day 1 (D1). Two stained bands with sizes of about 55 kDa and 27 kDa corresponding to the heavy chain and light chain of antibody were visualized on the gel. No antibody was detected in the flow-through (FT) after we passed the Day 6 culture supernatant on the Protein G column. Antibody elution was performed on 4 fractions (E1 to E4). Most abundant antibody was eluted in fractions E2 and E3, which was collected and pooled. (B) Using purified Lic5 for western blot on 97L cell lysate, a single band corresponding to the apparent molecule weight of CDH17 was revealed. (C) Using purified Lic5 for immunohistochemistry on human HCC tissue, discrete stains corresponding to the membrane and cytoplasmic localizations of CDH17 were detected, for which this staining pattern corresponded well to our published report
Fig. 2. Chemosensitizing effect of Lic5 (A) Single treatment of Lic5, cisplatin or epirubicin for 2 days inhibited the growth of cultured 97L and PLC cells when compared to the mouse IgG-treated cells in cell proliferation MTT assay. Further growth inhibition was observed when we treated the cultured cells under combined treatment of
As shown in Fig. 2B , a trend of tumor growth reduction was observed for every treatment group when compared to control group. We then compared the survival rate of orthotopic tumorbearing mice for each treatment group versus control group. The animal survival rate of Lic5 group reached 63.6%, which was much higher than that of the control group (26.6%). Although the survival rate between control group and epirubicin group was similar (26.6% versus 25%), combined treatment of Lic5 and epirubicin led to the most significant increase in survival rate to 81% among all experimental groups when compared to control group (p = 0.017) (Fig 2C) . However, such significant difference in survival for cisplatin group and cisplatin with Lic5 group did not reach any statistical significant values when compared to control group (data not shown). Taken together, this set of animal experiments has demonstrated the chemosensitizing effect of Lic5 in particular for epirubicin on tumor growth inhibition and survival rate induction.
Identification of CDR on Variable Regions of Lic5
Each monoclonal antibody has its unique variable regions on heavy chain and light chain, for which each of them is composed of a sequence of amino acids that determines the antigen binding property of this antibody. To obtain the variable region sequences from heavy chain and light chain of Lic5, we amplified each variable region using discrete primer pairs (Fig. 3 , left panel). After Sanger sequencing of the amplified products, the nucleotide sequences were translated into amino acid sequences by in silico method. Kabat numbering scheme and CDR definition were employed to identify the three CDRs on the variable regions of heavy chain and light chain of Lic5 using the deduced amino acid sequences (Fig. 3, right panel) .
DISCUSSION
This study continues our previous study on testing the anti-tumor and chemosensitizing effect of Lic5 on HCC. Our previous study examined such properties of Lic5 in a subcutaneous tumor xenograft model [5] , while this current study adopted the use of a more clinically relevant orthotopic tumor xenograft model. Although subcutaneous xenograft model is widely used for preclinical drug screening, the use of orthotopic xenograft model associates with added advantage by growing the tumor xenograft in the same environment as in the clinical situation. Therefore, orthotopic xenograft model is a more advanced animal model for preclinical drug testing, which can be used effectively for monitoring target site drug delivery, drug efficacy and pharmacokinetics [13] . Despite such advantage, establishment of orthotopic xenograft is more technically demanding due to the need to pre-label implanted tumor seeds for Our results have demonstrated the anti-tumor and chemosensitizing effects of Lic5 in treating HCC xenografts, implicating our in-house generated monoclonal antibody might be useful to treat other cancers apart from HCC. Lic5 was a monoclonal antibody produced in parallel with Lic3 by our team earlier using recombinant ectodomain 1-2 of CDH17 as an immunogen [3] . Since Lic5 targets the extracellular region of CDH17, it can bind to intact form or carboxylterminal truncated form of CDH17 when used for therapeutic purpose. Therefore, it is obvious Lic5 can be used to target other cancers with CDH17 overexpression. In addition to HCC, a number of cancers are found overexpressing CDH17, which include gastric adenocarcinoma, esophageal adenocarcinoma, and colorectal cancers [4, 14] . Among these cancer types, CDH17 overexpression was present in majority of colorectal and esophageal adenocarcinoma cancers [15, 16] . As such, these CDH17-overexpressing cancers might also be susceptible to the action of Lic5. Several studies performing CDH17 suppression counteracted tumorigenesis as manifested by reduced growth of cultured cells or tumor xenografts after treatment [17, 18] . Thus, targeting CDH17 to counteract tumorigenesis seems to work well in other cancers overexpressing CDH17 in addition to HCC. This opens up an opportunity of targeting CDH17 using Lic5 in other cancers for therapy.
In this and our previous studies, we have reported targeting CDH17 using Lic5 inactivated CDH17/β-catenin axis by interfering with the expression and localization of the axis components such as β-catenin [5] . Except for one study on gastric cancer that demonstrated similar result [19] , no other studies have yet reported this linkage between CDH17 and β-catenin-associated network. Instead in another cancer type, CDH17 was bridged to integrinrelated pathway during colorectal tumorigenesis because of the intrinsic integrin-binding affinity of CDH17 [20, 21] . CDH17 also affects two other tumorigenic pathways related to Ras/Raf/MEK/ERK and NFκB, such that its suppression inactivated these pathways in gastric cancer [22, 23] . Given these observations, it remains to be determined whether Lic5 could also block these pathways as a mean to suppress tumorigenesis.
Apart from testing the anti-tumor effects of Lic5, we also identified the three CDRs on each variable region on heavy and light chains of Lic5, for which these CDRs are responsible for determining antibody binding affinity and specificity [24] . As mouse antibody can elicit detrimental immunogenic responses in humans due to the human anti-mouse antibody reaction, humanization of Lic5, which is a mouse monoclonal antibody, is a prerequisite if we plan to use this antibody in humans in the future. With our identified CDRs on Lic5, next phase will involve generation of humanized Lic5 by grafting the identified CDRs and related amino acid sequence to a human antibody framework. The methodology for antibody humanization has evolved throughout these decades and a number of traditional and updated methods are developed for antibody humanization [25] . All these methods serve the same purpose by removing as much mouse sequences on antibody as possible, while at the same time retaining the essential CDR sequences. Other properties including stability and pharmacokinetics also need careful optimization during the process of antibody humanization [26] . For Lic5 with proven anti-tumor and chemosensitizing effects, we will perform antibody humanization. Upon completion, humanized Lic5 will then undergo extensive and vigorous testing before it can be considered for use in humans.
CONCLUSION
This paper examines the potential use of a monoclonal antibody Lic5 in treating HCC xenografts in nude mice. Results derived from this study have validated the preclinical use of Lic5 and envisioned the potential use of Lic5 as HCC therapy. 
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